Former Australian rugby international Nathan Charles, who defied a childhood diagnosis of cystic fibrosis to build a professional career in a high‑impact sport, has now been diagnosed with motor neurone disease (MND). The 37‑year‑old, who earned his first Test cap in 2014 and accumulated four appearances for the Wallabies – including a memorable 12‑12 draw against the All Blacks – announced the news alongside fellow recent retiree and former NRL star Jai Arrow, who was diagnosed with the same condition. MND is a collective term for a range of progressive neurological disorders that cause the motor neurons controlling voluntary muscles to deteriorate. The most prevalent form is amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease.
Both conditions lead to gradual muscle weakness, loss of coordination, and ultimately, a shortened lifespan, with no known cure at present. Charles disclosed his diagnosis during a candid interview with ex‑Wallaby lock and current commentator Justin Harrison on Stan Sport earlier this week.
He explained that the confirmation came only after a protracted period of uncertainty. "For a long time I just didn't know what was happening," Charles said, reflecting on the months of medical investigations. "I underwent countless tests, consulted numerous specialists, but nothing gave us a clear answer.
My health kept getting worse." He continued, "In the last few weeks I finally received a definitive diagnosis of motor neurone disease. It’s been incredibly challenging and overwhelming.
I’m fully aware there’s no cure, and that the disease will erode my physical capabilities and, ultimately, cut my life short." The former hooker retired from professional rugby in 2018 after stints with the Perth‑based Western Force and the Melbourne Rebels in Super Rugby, as well as spells in England with Gloucester, Bath and Wasps. Since hanging up his boots, Charles has remained active in the sport, serving as chief executive of Rugby Western Australia and contributing to the Sydney University Rugby Club. Charles’s personal health journey began in infancy. He was diagnosed with cystic fibrosis at three months old, a genetic disorder that primarily attacks the lungs and digestive system.
Doctors warned that his chances of surviving beyond ten years were slim. Defying those grim predictions, Charles not only survived but thrived, reaching the elite level of international rugby.
In a post on his personal website, he wrote, "I am constantly pushing the boundaries and am living proof that anything is possible. It is my personal mission to truly exceed the life expectancy of 37 years, which is the average for people with CF." Now, faced with a second, unrelated life‑threatening illness, he expressed a mix of resignation and irony.
"I was born with a life‑threatening illness. I've given that a red‑hot crack. Now this other thing comes along.
I find it quite ironic that something else will strike me down rather than what I've been dealing with for my whole life," he said. The rugby community has rallied around Charles.
The Wallabies, who are currently preparing for the Bledisloe Cup series against New Zealand, posted a supportive message on social media. Captain Harry Wilson wrote, "We know you have a tough time ahead, but we're with you every step of the way." Former England captain and 2003 World Cup winner Lewis Moody also announced his own MND diagnosis last year, highlighting a growing awareness of the disease within the sport. In recent years, the rugby world has mourned several high‑profile players lost to MND, including England legend Rob Burrow and Scottish great Doddie Weir, both of whom became powerful advocates for research and fundraising. Their stories, alongside Charles’s, underscore the urgent need for increased scientific investment and public education about motor neurone disease.
While there is currently no cure, research into ALS and related conditions is advancing. Clinical trials are exploring gene‑editing techniques, stem‑cell therapies, and novel drug candidates aimed at slowing neuronal degeneration. Organizations such as the Motor Neurone Disease Association and the ALS Association fund research, support services, and awareness campaigns worldwide. Charles has indicated that he intends to use his platform to raise awareness and support for MND research, just as he once did for cystic fibrosis.
By sharing his experience, he hopes to inspire others facing similar battles and to draw attention to the importance of early diagnosis and multidisciplinary care. The diagnosis marks a profound shift in Charles’s life, moving from the physically demanding world of professional sport to a personal fight against a relentless neurological disease. Yet, his track record of confronting adversity suggests he will approach this challenge with the same determination that propelled him from a three‑month‑old infant with a grim prognosis to a Wallaby international. The rugby community, fans, and medical advocates alike will be watching, supporting, and hoping for breakthroughs that could one day turn a diagnosis like Charles’s into a manageable condition rather than a terminal one.